Real-World Assessment of Myelodysplastic Syndrome: Japanese Claims Data Analysis

References

• Zeidan AM , ShallisRM, WangR, DavidoffA, MaX. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev.34, 1–15 (2019).
   PubMed Web of Science ®Google Scholar
• Ma X . Epidemiology of myelodysplastic syndromes. Am. J. Med.125(Suppl. 7), S2–S5 (2012).
   Web of Science ®Google Scholar
• Germing U , OlivaEN, HiwaseD, AlmeidaA. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. Hemasphere3(6), e314 (2019).
   PubMed Web of Science ®Google Scholar
• Chihara D , ItoH, KatanodaKet al. Incidence of myelodysplastic syndrome in Japan. J. Epidemiol.24(6), 469–473 (2014).
   Web of Science ®Google Scholar
• Miyazaki Y , TuechlerH, SanzGet al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: analysis from the International Working Group for Prognosis of MDS. Leuk. Res.73, 51–57 (2018).
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hematology . Hematologic malignancy treatment guidelines: myelodysplastic syndromes. (2018).
   Google Scholar
• Steensma D . Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J.8(5), 47 (2018).
   PubMed Web of Science ®Google Scholar
• Santini V . Treatment of low-risk myelodysplastic syndromes. Hematol. Am. Soc. Hematol. Educ. Program2(1), 462–469 (2016).
   Google Scholar
• Steensma D . Graphical representation of clinical outcomes for patients with myelodysplastic syndromes. Leuk. Lymphoma57(1), 17–20 (2016).
   PubMed Web of Science ®Google Scholar
• Gangat N , PatnaikMM, BegnaKet al. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer J.6(4), e414 (2016).
   PubMedGoogle Scholar
• Cogle CR , KurtinSE, BentleyTGet al. The incidence and health care resource burden of the myelodysplastic syndromes in patients in whom first-line hypomethylating agents fail. Oncologist22(4), 379–385 (2017).
   PubMed Web of Science ®Google Scholar
• Bell JA , GalaznikA, BlazerMet al. Economic burden of patients treated for higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States. Pharmacoecon. Open3(2), 237–245 (2019).
   PubMed Web of Science ®Google Scholar
• Lucioni C , FinelliC, MazziS, OlivaE. Costs and quality of life in patients with myelodysplastic syndromes. Am. J. Blood Res.3(3), 246–259 (2013).
   PubMedGoogle Scholar
• Goldberg SL , ChenE, SasaneM, PaleyC, GuoA, LaouriM. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion52(10), 2131–2138 (2012).
   PubMed Web of Science ®Google Scholar
• Clark O , FaleirosJF. Cost of the treatment of myelodisplastic syndrome in Brazil. Rev. Bras. Hematol. Hemoter.33(1), 31–34 (2010).
   Google Scholar
• Japanese Society for Pharmacoepidemiology . Databases available for pharmacoepidemiology researches in Japan (information obtained from survey answers as of August 2020) (2020). www.jspe.jp/mt-static/FileUpload/files/JSPE_DB_TF_E.pdf
   Google Scholar
• Tsutsué S , TobinaiK, YiJ, CrawfordB. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS ONE15, 1–18 (2020).
   Web of Science ®Google Scholar
• Tsutsué S , SuzukiT, KimH, KuanWY, CrawfordB. Real-world assessment of nationwide health economic burden and treatment-based survival for current myelodysplastic syndromes treatment practice in Japan. Blood136(Suppl. 1), 36–37 (2020).
   Google Scholar
• Bell JA , GalaznikA, BlazerMet al. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leuk. Lymphoma60(1), 49–59 (2019).
   PubMed Web of Science ®Google Scholar
• Bell JA , GalaznikA, HuelinRet al. Systematic literature review of treatment options and clinical outcomes for patients with higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia. Clin. Lymphoma Myeloma Leuk.18(4), e157–e166 (2018).
   PubMed Web of Science ®Google Scholar
• Kurumaddali A , SalemAH, AgarwalSK. A meta-analysis of higher-risk myelodysplastic syndrome trials to evaluate the relationship between short-term endpoints and overall survival. J. Cancer10(22), 5427 (2019).
   Web of Science ®Google Scholar
• Wang N , XuH, LiQet al. Patients of myelodysplastic syndrome with mild/moderate myelofibrosis and a monosomal karyotype are independently associated with an adverse prognosis: long-term follow-up data. Cancer Manag. Res.12, 5881 (2020).
   PubMed Web of Science ®Google Scholar
• Tsutsué S , TobinaiK, YiJ, CrawfordB. Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study. Future Oncol.17(4), 455–469 (2021).
   PubMed Web of Science ®Google Scholar
• Consumer Price Index 2015 – Base Consumer Price Index Annual Report Yearly (2019). www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200573&tstat=000001084976&cycle=7&year=20190&month=0&tclass1=000001085975
   Google Scholar
• Population inference (2019). www.stat.go.jp/data/jinsui/pdf/201901.pdf
   Google Scholar
• Wang F , NiJ, WuL, WangY, HeB, YuD. Gender disparity in the survival of patients with primary myelodysplastic syndrome. J. Cancer10(5), 1325–1332 (2019).
   Web of Science ®Google Scholar
• Cogle CR . Incidence and burden of the myelodysplastic syndromes. Curr. Hematol. Malig. Rep.10(3), 272–281 (2015).
   PubMed Web of Science ®Google Scholar
• Mozessohn L , CheungM, MittmannN, EarleCC, LiuN, BucksteinR. High healthcare utilization and costs in patients with higher-risk MDS/low blast count AML treated with azacitidine in Ontario, Canada. Blood132(Suppl. 1), 834 (2018).
   Google Scholar
• KÜhne F , MittendorfT, GermingUet al. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer’s perspective. Ann. Hematol.89, 1239–1247 (2010).
   Web of Science ®Google Scholar
• Japanese Society for Hematopoietic Cell Transplantation . Guideline for hematopoietic cell transplantation in adult myelodysplastic syndromes and myeloproliferative neoplasms, third edition (2021). www.jshct.com/uploads/files/guideline/03_05_mds-mpn03.pdf
   Google Scholar
• Wang R , GrossCP, FrickKet al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk. Res.36(11), 1370–1375 (2012).
   PubMed Web of Science ®Google Scholar
• Greenberg PL , CoslerLE, FerroSA, LymanGH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J. Natl Compr. Cancer Netw.6(9), 942–953 (2008).
   PubMedGoogle Scholar
• Salas-Vega S , ShearerE, MossialosE. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc. Sci. Med.258(113042), (2020).
   Google Scholar
• Zeidan AM , WangR, DavidoffAJet al. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer122(10), 1598–1607 (2016).
   PubMed Web of Science ®Google Scholar